Nowadays, only mutations in ARID1A have been more comprehensively studied in ovarian cancer, explaining not only that their mutations cause an increase in MYC expression and affect tumour progression, but also that therapies targeting ARID1A mutations have emerged in the clinic. This evidence concerns the gene MYC and neoplasm.